The Effects of Nanocurcumin on Serum Oxidative Stress,Inflammation,Adiponectin and NF-kB in Blood Mononuclear Cells in Metabolic Syndrome Patients (Nuclear Factor-κB)

National Nutrition and Food Technology Institute

Status

Unknown

Conditions

Metabolic Syndrome

Treatments

Dietary Supplement: placebo

Dietary Supplement: nanomicielle curcumin

Study type

Interventional

Funder types

Other

Identifiers

NCT03514667

188

Details and patient eligibility

About

Metabolic syndrome is a public health challenge that includes a range of conditions including abdominal obesity, dyslipidemia, hyperglycemia, and hypertension. The syndrome is associated with an increase in the risk of Cardiovascular disease and death. Curcumin is a very active compound obtained from turmeric root. Curcumin has antioxidant and anti-inflammatory effects, and is also involved in the regulation of several signaling pathways. Since curcumin powder has low bioavailability, fast metabolism and low absorption, nanomicielle curcumin will be used in this study. Therefore, this study is planned to determine the effects of supplementation of nanomicielle curcumin on oxidative stress, systemic inflammation, adiponectin in serum and NF-kB in peripheral blood mononuclear cells in patients with metabolic syndrome.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

25<body mass index >40
waist circumference >102 cm in men or >88 cm in women
Fasting blood glucose >100 mg/dL
Triglycerides (TG) > 150 mg/dL
High density lipoprotein cholesterol (HDL-C) <50 in women or <40 in men
Systolic blood pressure (SBP) >130 mmHg and diastolic blood pressure (DBP) >85mmHg

Exclusion criteria

insulin administration for diabetes control
hypo- or hyperthyroidism,
renal failure or other chronic diseases
pregnancy and breastfeeding
taking weight loss supplements and obeying unusual weight loss plans

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

50 participants in 2 patient groups, including a placebo group

intervention group

Active Comparator group

Description:

80 mg nanomicielle curcumin capsules once a day for 12 weeks

Treatment:

Dietary Supplement: nanomicielle curcumin

control group

Placebo Comparator group

Description:

placebo capsules once a day for 12 weeks

Treatment:

Dietary Supplement: placebo

Trial contacts and locations

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms